HY 0011
Alternative Names: HY-0011Latest Information Update: 28 Aug 2023
At a glance
- Originator Sichuan Huiyu Pharmaceutical
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Solid tumours
Most Recent Events
- 25 Jul 2023 Early research in Solid tumours in China (Parenteral) (Sichuan Huiyu Pharmaceutical pipeline, July 2023)
- 25 Jul 2023 Early research in Solid tumours in Europe (Parenteral) (Sichuan Huiyu Pharmaceutical pipeline, July 2023)